Lyell Immunopharma (LYEL)
(Real Time Quote from BATS)
$1.46 USD
-0.03 (-2.01%)
Updated Aug 5, 2024 02:18 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Lyell Immunopharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -234.63 | -183.12 | -250.22 | -204.47 | -129.38 |
Depreciation/Amortization & Depletion | 10.65 | 17.09 | 15.53 | 4.83 | -0.26 |
Net Change from Assets/Liabilities | 3.42 | -82.01 | 0.34 | -0.34 | 110.81 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 56.86 | 78.49 | 108.11 | 39.10 | 58.31 |
Net Cash From Operating Activities | -163.69 | -169.56 | -126.25 | -160.87 | 39.47 |
Property & Equipment | -2.69 | -24.28 | -65.50 | -51.48 | -16.05 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 186.73 | 12.74 | -56.07 | -222.04 | -406.39 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 184.05 | -11.54 | -121.57 | -273.52 | -422.43 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.20 | 11.10 | 401.24 | 476.79 | 351.16 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.46 | -0.46 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 1.74 | 10.64 | 401.24 | 476.79 | 351.16 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 22.10 | -170.46 | 153.42 | 42.40 | -31.80 |
Cash at Beginning of Period | 123.83 | 294.29 | 140.87 | 98.47 | 130.28 |
Cash at End of Period | 145.93 | 123.83 | 294.29 | 140.87 | 98.47 |
Diluted Net EPS | -0.93 | -0.74 | -1.84 | NA | NA |
Fiscal Year End for Lyell Immunopharma, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -60.67 | -234.63 | -181.70 | -130.85 |
Depreciation/Amortization & Depletion | NA | 0.66 | 10.65 | 8.98 | 6.16 |
Net Change from Assets/Liabilities | NA | -3.24 | 3.42 | 1.70 | -0.73 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 21.23 | 56.86 | 47.96 | 40.04 |
Net Cash From Operating Activities | NA | -42.02 | -163.69 | -123.06 | -85.37 |
Property & Equipment | NA | -0.03 | -2.69 | -2.66 | -2.47 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 22.02 | 186.73 | 287.40 | 187.53 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 21.99 | 184.05 | 284.74 | 185.07 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.10 | 2.20 | 1.32 | 1.25 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.08 | -0.46 | -0.33 | -0.12 |
Net Cash from Financing Activities | NA | 0.03 | 1.74 | 0.98 | 1.13 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -20.00 | 22.10 | 162.66 | 100.82 |
Cash at Beginning of Period | NA | 145.93 | 123.83 | 123.83 | 123.83 |
Cash at End of Period | NA | 125.94 | 145.93 | 286.50 | 224.65 |
Diluted Net EPS | NA | -0.24 | -0.20 | -0.20 | -0.26 |